Study of immunotherapy with chemo-radiation for lung metastases from nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This trial tests whether combining an immunotherapy drug (PD-1 inhibitor) with chemotherapy and radiation can help treat nasopharyngeal cancer that has spread to the lungs. It is for people whose cancer returned more than six months after initial treatment and who haven't had immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have nasopharyngeal cancer (a type of head and neck cancer) that has spread to the lungs, chest, or lining of the lungs
- Your cancer returned more than six months after your first treatment
- You have not had immunotherapy (like a PD-1 inhibitor) before
- You have not had chemotherapy for cancer that has spread to other parts of the body
- Your major organs (kidneys, liver, bone marrow) are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Hear when a new Lung Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.